Please ensure Javascript is enabled for purposes of website accessibility

Why Tilray Stock Rose Today

By Joe Tenebruso – Aug 18, 2021 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The marijuana giant has its sights set on the potentially massive U.S. cannabis market.

What happened

Shares of Tilray (TLRY 1.92%) climbed on Wednesday after the Canadian cannabis company announced a deal with American marijuana retailer MedMen Enterprises (MMNFF -0.96%). By the close of trading, Tilray's stock price was up 1.1% after rising as much as 7.2% earlier in the day.

So what

Tilray agreed to purchase MedMen's convertible notes from private equity firm Gotham Green Partners. The deal could position Tilray to quickly enter the U.S. market should federal legalization progress.

"Backed by accelerating trends toward legalization globally, we are focused on building the world's leading cannabis-focused, consumer-branded company with a goal of $4 billion of revenue by the end of our fiscal 2024," Tilray CEO Irwin Simon said in a press release. "The investment we are announcing in MedMen securities today, one of the most recognized brands in the $80 billion U.S. cannabis market, is a critical step toward delivering on our objective."

A person is holding a cannabis leaf in front of a U.S. flag.

Image source: Getty Images.

Under the terms of the deal, Tilray and other investors will establish a limited partnership that will purchase roughly $165.8 million of MedMen's debt and warrants. Tilray's stake in the limited partnership will essentially give it the right to acquire 21% of MedMen's Class B shares. 

Now what

Tilray would like to pay for the deal in stock. Management is asking its investors to authorize the issuance of 9 million shares at its meeting tomorrow. If Tilray's stock owners vote no, the company could be forced to pay in cash.

"Our ability to maximize value from this game-changing transaction rests on the support of our shareholders," Simon said.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray, Inc. Stock Quote
Tilray, Inc.
$3.72 (1.92%) $0.07
MedMen Enterprises Inc. Stock Quote
MedMen Enterprises Inc.
$0.03 (-0.96%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.